20314-75-4

Usage

Uses

Used in Pharmaceutical Industry:
(1S,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl morpholin-4-ylacetate is used as a building block for the synthesis of various drugs and pharmaceutical products due to its potential biological activity and unique structure.
Used in Medicinal Chemistry Research:
(1S,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl morpholin-4-ylacetate is used as a research compound in medicinal chemistry for the development of new medications and understanding its potential applications in drug discovery.
Used in Drug Discovery:
(1S,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl morpholin-4-ylacetate is used in drug discovery for exploring its potential as a new medication and its role in the development of innovative pharmaceutical products.

Upstream product

• 464-45-9 endo-borneol 
• 110-91-8 morpholine 
• 75556-46-6 (1S,2R,4S)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl 2-chloroacetate 
• 464-48-2 (1S)-camphor 
• 89299-71-8 (1S,2S,4S)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl 2-chloroacetate 

Relevant academic research and scientific papers

Discovery of a New Class of Inhibitors of Vaccinia Virus Based on (?)-Borneol from Abies sibirica and (+)-Camphor

A series of the bornyl ester/amide derivatives with N-containing heterocycles were designed and synthesized as vaccinia virus (VV) inhibitors. Bioassay results showed that among the designed compounds, derivatives 6, 13, 14, 34, 36 and 37 showed the best inhibitory activity against VV with the IC50 values of 12.9, 17.9, 3.4, 2.5, 12.5 and 7.5 μm, respectively, and good cytotoxicity. The primary structure–activity relationship (SAR) study suggested that the combination of a saturated N-heterocycle, such as morpholine or 4-methylpiperidine, and a 1,7,7-trimethylbicyclo[2.2.1]heptane scaffold was favorable for antiviral activity.

Synthesis and in vitro study of novel borneol derivatives as potent inhibitors of the influenza A virus

Herein, we present the design and synthesis of a series of novel heterocyclic derivatives of (-)-borneol and (-)-isoborneol as potent inhibitors of the influenza A virus. All compounds were tested for their toxicity against MDCK cells and for virus-inhibiting activity against the influenza virus A/Puerto Rico/8/34 (H1N1). Compounds 7, 16 and 26 containing a morpholine fragment exhibited the highest efficiency as agents inhibiting the replication of the influenza virus A(H1N1) with selectivity indices of 82, 45 and 65, correspondingly. Derivatives 9 (SI = 23) and 18 (SI = 25) containing a 1-methylpiperazine motif showed moderate antiviral activity. Structure-activity analysis of this new series of borneol derivatives revealed that a 1,7,7-trimethylbicyclo[2.2.1]heptan scaffold is required for the antiviral activity.

Monoterpenoid-based inhibitors of filoviruses targeting the glycoprotein-mediated entry process

In this study, we screened a large library of (+)-camphor and (?)-borneol derivatives to assess their filovirus entry inhibition activities using pseudotype systems. Structure-activity relationship studies revealed several compounds exhibiting submicromolar IC50 values. These compounds were evaluated for their effect against natural Ebola virus (EBOV) and Marburg virus. Compound 3b (As-358) exhibited the good antiviral potency (IC50 = 3.7 μM, SI = 118) against Marburg virus, while the hydrochloride salt of this compound 3b·HCl had a strong inhibitory effect against Ebola virus (IC50 = 9.1 μM, SI = 31) and good in vivo safety (LD50 > 1000 mg/kg). The results of molecular docking and in vitro mutagenesis analyses suggest that the synthesized compounds bind to the active binding site of EBOV glycoprotein similar to the known inhibitor toremifene.